ARDEA BIOSCIENCES, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1994-01-01

Employees: 107

Market Cap: -

Website: http://www.ardeabio.com

Clinical Trials

Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

Phase 1

Completed

Conditions: Gout

Interventions: Drug: lesinurad/allopurinol 200/300 FDC tablets
Drug: lesinurad 200 mg
Drug: allopurinol 300 mg

First Posted Date: 2017-09-05

Last Posted Date: 2018-11-07

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 32

Registration Number: NCT03272425

Locations: 🇧🇷
CAEP - Centro Avançado de Estudos e Pesquisas Ltda., Campinas, Sao Paulo, Brazil

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: lesinurad/allopurinol 200/300 FDC tablet
Drug: lesinurad 200 mg
Drug: allopurinol 300 mg

First Posted Date: 2016-09-02

Last Posted Date: 2017-06-16

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 28

Registration Number: NCT02888054

RDEA3170 PK/PD Study

Phase 1

Completed

Conditions: Gout

Interventions: Drug: RDEA3170 4.5 mg
Drug: RDEA3170 6 mg
Drug: RDEA3170 12 mg

First Posted Date: 2015-11-20

Last Posted Date: 2016-09-02

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 40

Registration Number: NCT02608710

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: lesinurad/allopurinol 200/300 FDC tablets
Drug: lesinurad 200 mg
Drug: lesinurad/allopurinol 200/200 FDC tablets
Drug: allopurinol 200 mg
Drug: allopurinol 300 mg

First Posted Date: 2015-10-21

Last Posted Date: 2016-12-19

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 116

Registration Number: NCT02581553

Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

Phase 2

Completed

Conditions: Gout

Interventions: Drug: RDEA3170 2.5 mg
Drug: allopurinol 300 mg

First Posted Date: 2015-07-15

Last Posted Date: 2018-01-23

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 41

Registration Number: NCT02498652

RDEA3170 Tablet and Capsule Bioavailability Study

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: RDEA3170, 5 mg
Drug: RDEA3170,10 mg
Drug: RDEA3170, 2.5 mg
Drug: RDEA3170, 10 mg

First Posted Date: 2015-05-19

Last Posted Date: 2018-08-20

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 35

Registration Number: NCT02448368

IVIVR Assessing PK Parameters Used to Establish Bioequivalence

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Zyloprim® 300 mg
Drug: Allopurinol 300 mg; undergranulated, high hardness condition
Drug: Allopurinol 300 mg; alternative condition 2
Drug: Allopurinol 300 mg; alternative condition 3

First Posted Date: 2015-03-25

Last Posted Date: 2016-01-01

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 20

Registration Number: NCT02398448

DECT Study in Allopurinol-Treated Gout Patients

Completed

Conditions: Gout

Interventions: Procedure: DECT scan

First Posted Date: 2015-03-19

Last Posted Date: 2017-01-25

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 223

Registration Number: NCT02393560

RDEA3170 Bioavailability Study

Phase 1

Completed

Conditions: Gout

Interventions: Drug: RDEA3170 10 mg
Drug: RDEA3170 2.5 mg

First Posted Date: 2015-01-13

Last Posted Date: 2017-10-13

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 15

Registration Number: NCT02336594

RDEA3170 and Allopurinol Combination Study in Gout Subjects

Phase 1

Completed

Conditions: Gout

Interventions: Drug: RDEA3170 10 mg
Drug: allopurinol 300 mg

First Posted Date: 2014-10-31

Last Posted Date: 2017-12-20

Lead Sponsor: Ardea Biosciences, Inc.

Target Recruit Count: 12

Registration Number: NCT02279641

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy